Nuclear Factor-κB Signaling in Murine Models of Malignant Pleural Mesothelioma

Our plain-English summary of Nuclear Factor-κB Signaling in Murine Models of Malignant Pleural Mesothelioma, by B. Deng, I. Giopanou, L. Asarian, et al (Cancers, 2026).

The study

• Authors: B. Deng, I. Giopanou, L. Asarian, I. Lilis, J. Jia, M. Lianou, D. Simoglou, G. Ntaliarda, T.A. Adamide, I.E. Fernandez, G.T. Stathopoulos
• Journal: Cancers
• Published: 2026;18(18)
• Read it: PubMed · Publisher · Free full text

Abstract

Background: Malignant pleural mesothelioma (MPM) is an aggressive asbestos-associated cancer in which inflammatory pathways may contribute to tumor behavior. NF-κB signaling is a central mediator of inflammation and cell survival, but the relative contributions of its associated enzymes, IKKα- and IKKβ, in MPM models remain incompletely understood.

Methods: We characterized the involvement of IKKα- and IKKβ in tumor formation using several in vitro approaches and the intrapleural or subcutaneous delivery of three murine MPM cell models (AB2, AE17 and KPM1). The experimental approaches included shRNA silencing of Chuk and Ikbkb-the genes encoding the activity of IKKα- and IKKβ-and tumor growth, apoptosis and colony formation measurements. Exploratory pathway and transcriptional analyses were carried out following RNA-sequencing of our murine cell lines and a publicly available human gene expression dataset was also analyzed to provide complementary evidence.

Results: Activation of the IKKα- and IKKβ was confirmed in the AB2, AE17 and KPM1 cell lines. Silencing both Chuk and Ikbkb decreased target and cross-target transcripts and metabolic growth. Importantly, Chuk silencing was associated with increased early apoptotic staining in AE17 and KPM1 cells, increased late apoptotic staining in AE17 cells and reduced colony formation in all cell models. Furthermore, Chuk-associated effects on tumor burden and activity were more notable than Ikbkb-associated effects in both intrapleural and subcutaneous tumor formation parameters. Finally, while canonical NF-κB gene-set clustering in both human and murine tumor samples identified specific and shared pathways and transcriptional profiles supporting the in vitro murine assay findings, the analyses remained exploratory and did not specifically establish target dependency.

Conclusions: Our data support the involvement of IKK/NF-κB-associated signaling in cell survival, clonogenicity and tumor growth in several MPM murine cell models and identify Chuk-related signaling as a promising target in future studies.

In plain English

This was a laboratory study in mouse malignant pleural mesothelioma (MPM) models, a cancer the authors describe as asbestos-associated; no asbestos exposure was performed. Three murine MPM cell lines (AB2, AE17, KPM1) were used, with lentiviral shRNA silencing of Chuk and Ikbkb, the genes encoding IKKalpha and IKKbeta. Silenced cells were tested for metabolic growth (MTT), colony formation and apoptosis, and injected intrapleurally or subcutaneously into BALB/c or C57BL/6 mice; RNA sequencing of the cell lines and a public human dataset (GSE51024: 55 MPM and 41 paired non-tumor lung samples) were also analysed. Chuk silencing significantly increased early apoptosis in AE17 and KPM1, late apoptosis in AE17, reduced MTT signal in all three lines and reduced colony formation in all models; Ikbkb silencing reduced MTT only in KPM1 and did not affect colony formation. In vivo, Chuk silencing reduced tumour parameters in all models, Ikbkb silencing in AB2 and AE17 only. The authors concluded IKK-associated signalling supports experimental MPM, with IKKalpha the most consistent.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Experimental laboratory study: in vitro assays and RNA sequencing in three murine MPM cell lines, intrapleural and subcutaneous mouse tumour models, plus exploratory analysis of a publicly available human gene-expression dataset
• Who was studied: Murine MPM cell lines AB2 (BALB/c), AE17 and KPM1 (C57BL/6), human control cell lines MET5A, MSTO-211H and ZL34, BALB/c and C57BL/6 mice (sex-, weight- and age-matched, 20-25 g, 6-12 weeks), and a public human dataset of 55 MPM tumours and 41 paired non-tumour lung parenchyma samples; work done in Munich, Germany and Patras, Greece
• Exposure: Not an asbestos exposure study: the manipulation tested was lentiviral shRNA silencing of Chuk (IKKalpha) and Ikbkb (IKKbeta) versus a scrambled control sequence in the three murine MPM cell lines
• Main results:
  • In apoptosis assays, Ikbkb silencing had no effect in any line and Chuk silencing had no effect in AB2 cells, while Chuk silencing significantly increased early apoptosis in AE17 and KPM1 and late apoptosis in AE17
  • Chuk silencing reduced growth-associated metabolic (MTT) signal in all three cell models; Ikbkb silencing reduced MTT signal only in KPM1, and colony formation fell with Chuk silencing in all models but not with Ikbkb silencing
  • After intrapleural delivery of AB2 cells, tumour size and pleural fluid fell with either Chuk or Ikbkb silencing, but nucleated pleural fluid cells fell only with Chuk silencing; AE17-derived tumours gave similar results
  • For KPM1 (KrasG12D mutation and Trp53 loss), growth parameters decreased only with Chuk silencing, not Ikbkb silencing
  • RNA sequencing of the silenced cell lines identified 188 differentially expressed genes versus control transfections (p less than 0.05), with 76 up- and 49 down-regulated when both genes were silenced
  • In the human dataset, unsupervised clustering using canonical (23 genes) and atypical (17 genes) NF-kB gene lists gave four and three clusters respectively, with cluster 2 containing more tumour samples than the other clusters
• The authors' conclusion: The authors concluded that their data support a role for IKK-associated signalling in experimental MPM, with IKKalpha depletion producing the most consistent effects, and they put IKKalpha forward as a therapeutic candidate for further study
• Limitations the authors state:
  • The authors state the silencing experiments used single shRNA reagents with cross-target mRNA effects and no independent shRNAs or rescue experiments, limiting target-specific attribution
  • The authors state the apoptosis finding was seen in the two Kras-mutant lines but not in AB2, and say this requires further validation in isogenic models
  • The authors state knockdown was assessed mainly by qPCR and qualitative immunofluorescence without quantitative immunoblotting or comprehensive functional analysis of NF-kB signalling, preventing precise assignment of tumour phenotypes to IKKalpha or IKKbeta
  • The authors state the pathway and transcriptional analyses were exploratory and did not establish target dependency

Topics

Medical terms in this study, explained in our Lexicon: Pleural Mesothelioma, Inflammation, Apoptosis, Tumor Burden.

Related studies

• KRAS signaling in malignant pleural mesothelioma — A. Marazioti, A.C. Krontira, et al. (2022)
• The duration of nuclear extracellular signal-regulated kinase 1 and 2 signaling during cell cycle reentry distinguishes proliferation from apoptosis in response to asbestos — Z. Yuan, D.J. Taatjes, et al. (2004)
• Asbestos Induces Oxidative Stress and Activation of Nrf2 Signaling in Murine Macrophages: Chemopreventive Role of the Synthetic Lignan Secoisolariciresinol Diglucoside (LGM2605) — R.A. Pietrofesa, A. Velalopoulou, et al. (2016)
• Establishment of a murine model of malignant mesothelioma — M.R. Davis, L.S. Manning, et al. (1992)
• Targeting the inhibitory receptor CTLA-4 on T cells increased abscopal effects in murine mesothelioma model — L. Wu, M.O. Wu, et al. (2015)
• Gene expression profiles reveal increased mClca3 (Gob5) expression and mucin production in a murine model of asbestos-induced fibrogenesis — T. Sabo-Attwood, M. Ramos-Nino, et al. (2005)

Browse more research in Cancers, or return to medical research.